Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

3.200 +0.040 (+1.27%)
Streaming Delayed Price Updated: 3:01 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 275,155
Open 3.160
Bid (Size) 3.200 (1)
Ask (Size) 3.210 (5)
Prev. Close 3.160
Today's Range 3.085 - 3.265
52wk Range 2.375 - 5.540
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga

Performance

YTD
-25.4%
-25.4%
1 Month
+18.1%
+18.1%
3 Month
+1.3%
+1.3%
6 Month
-32.5%
-32.5%
1 Year
+15.9%
+15.9%

More News

Read More
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
Via InvestorPlace
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
Via InvestorPlace
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Via InvestorPlace
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?
Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market
What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?
The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 3.200
When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 07/31/25 03:01 PM ET
What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 72.02M
How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?
Eledon Pharmaceuticals, Inc. - Common Stock has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.